Cybin is trading 4.6% up at $6.81 following positive analyst sentiment and reports of a reinforced balance sheet.
- Analysts highlighted clinical progress and positive sentiment surrounding the company’s psychedelic programs.
- Market commentary pointed to a strengthened cash position, providing a more stable financial outlook for the company's development pipeline.
- The upward move appears driven primarily by external analyst coverage rather than a specific company earnings release or major announcement.